09-04-2025 / Chuanxin Liu, PhD, Head of Viral Vector R&D, GenScript Biotech Corporation
Watch this webinar to gain insights into lentivirus innovations driving breakthroughs in in vivo CAR-T and gene delivery.
Learn More
10-18-2024 / Dr. Hui Foon Tan, Sr. Global Product Manager - Antibody, GenScript Biotech
Discover how GenScript's cutting-edge rabbit anti-idiotypic antibody (Anti-ID Ab) development technology enhances pharmacokinetics (PK) and anti-drug antibody (ADA) assays.
Learn More
07-18-2024 / Dr. Yerim Kwon, Field Application Scientist, APAC region
Antibodies play a crucial role in biological and biochemical research, and their importance in therapeutic applications is increasing.
Learn More
06-21-2024 / Dr. Carter Hao
Monoclonal antibodies (mAbs) have become essential in treating a wide spectrum of diseases, with over 100 therapeutic antibody products now approved and commercially available.
Learn More
06-18-2024 / Dr. Wang Sai, Senior Scientist (Protein), GenScript
The webinar will introduce the advantages of bispecific antibodies (bsAbs), their mechanism of action (MOA), and the development history of bsAb platform.
Learn More
03-06-2024 / Dr. Paul Maciocia, Clinical Scientist and Honorary Consultant Haematologist, Cancer Institute, University College London
Discover a groundbreaking webinar exploring the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL).
Learn More
12-08-2023 / Dr. Xiaoyu Chen, Protein Senior Scientist, GenScript
Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies (BsAb). You will learn about how bispecific antibodies (BsAb) enable new therapeutic applications
Learn More
05-18-2023 / Dr. Hui Foon Tan, PhD, Sr. Global Product Manager - Antibody, GenScript Biotech
Join us in our webinar to learn more how our anti-idiotypic antibody platform can help you develop highly sensitive and specific polyclonal and monoclonal anti-ID antibodies to best suit your particular downstream applications with shorter turnaround time
Learn More